{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 0.5 mg/kg belantamab mafodotin intravenous (IV) infusion as powder for solution once every 4 weeks (Q4W) infused over 30- 60 minutes on day 1 of each 28-day cycle in combination with 100 mg Nirogacestat administered orally twice a day (BID) up to Day 28. Along with 4 mg Pomalidomide orally per day (QD) on Days 1-21 of each 28-day cycle and Dexamethasone 40mg (20 mg for participants \\>75 years old or BMI \\<18.5 kg/m\\^2) administered orally on days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG000","title":"0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone"}],"populationDescription":"No participants were enrolled as CE Phase was not initiated due to business strategic reason.","reportingStatus":"POSTED","timeFrame":"Up to 137 weeks","title":"CE Phase: Titer of ADAs Against Belantamab Mafodotin","type":"SECONDARY"}